Discovery of TL10: A Soluble and Long-Acting MC4R Agonist with Tunable Lipidation for Sustained Pharmacological Activity.
TL10 shows promise as a long-acting MC4R agonist with a significantly extended half-life and potential for sustained weight loss in mice. Further studies are needed to evaluate its effects in humans.
Where it sits
this study against the rest of the setmelanotide corpusSummary and findings
This study reports the discovery of TL10, a soluble and long-acting MC4R agonist. TL10 demonstrated a plasma half-life of approximately 33.4 hours and a 34-fold increase compared to setmelanotide. In diet-induced obese mice, TL10 administration resulted in sustained weight loss and appetite suppression.
Abstract
The development of long-acting MC4R peptide agonists remains challenging due to rapid clearance and structural sensitivity, where conventional permanent lipidation strategies often impair receptor engagement. Here, we report the discovery and characterization of TL10, a soluble, long-acting MC4R agonist achieved via a tunable lipidation strategy that transiently masks the peptide to extend circulation while preserving activity. TL10 exhibited controlled release kinetics and a markedly prolonged plasma half-life (t1/2 ≈ 33.4 h), representing a 34-fold increase compared to setmelanotide. In diet-induced obese mice, Q3D administration of TL10 elicited sustained weight loss and appetite suppression, matching or exceeding daily setmelanotide under the tested conditions. High aqueous solubility (180 mg/mL) facilitated concentrated formulations, and a 28 day repeat-dose study indicated a favorable safety profile. Collectively, these results demonstrate that TL10 is a promising long-acting candidate with sustained pharmacological activity, providing a practical framework for the development of modification-sensitive peptides.
Background
The study addresses the challenge of developing long-acting MC4R peptide agonists, which are often limited by rapid clearance and structural sensitivity. Previous approaches using permanent lipidation strategies have been shown to impair receptor engagement. This research is significant as it explores a novel tunable lipidation strategy that may enhance the pharmacological profile of MC4R agonists.
Methods
The study involved the characterization of TL10, focusing on its pharmacokinetic properties and biological activity in diet-induced obese mice. Specifics regarding the population size, dosing regimen, and duration were not provided in the abstract. The primary outcomes measured included plasma half-life and effects on weight and appetite.
Results
The primary endpoint indicated that TL10 had a plasma half-life of approximately 33.4 hours, representing a 34-fold increase compared to setmelanotide. TL10 also demonstrated high aqueous solubility at 180 mg/mL and elicited sustained weight loss and appetite suppression in the tested mice.
Interpretation
The findings suggest that TL10 may offer a significant improvement over setmelanotide in terms of pharmacokinetics and sustained activity. However, while the effect size appears promising, it is important to consider that the results are based on animal models, which may not fully translate to human outcomes. The study lacks detailed information on sample size and potential confounding factors.
Key findings
- t1/2 ≈ 33.4 h for TL10, a 34-fold increase compared to setmelanotide.
- High aqueous solubility of TL10 at 180 mg/mL.
- Sustained weight loss and appetite suppression in diet-induced obese mice with TL10.
- 28 day repeat-dose study indicated a favorable safety profile.
Limitations
- Animal study with diet-induced obese mice.
- Specific sample size not reported.
- No human data provided.
- Lack of detailed dosing regimen and duration.